IntelGenx Technologies Corp. (IGXT)

OTCMKTS: IGXT · Delayed Price · USD
0.184
+0.012 (6.98%)
Mar 27, 2024, 3:49 PM EDT - Market open
Market Cap 32.14M
Revenue (ttm) 1.04M
Net Income (ttm) -10.23M
Shares Out 174.66M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,727
Open 0.172
Previous Close 0.172
Day's Range 0.160 - 0.184
52-Week Range 0.090 - 0.260
Beta 2.42
Analysts n/a
Price Target n/a
Earnings Date Aug 14, 2023

About IGXT

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 48
Stock Exchange OTCMKTS
Ticker Symbol IGXT
Full Company Profile

Financial Performance

In 2023, IGXT's revenue was $1.04 million, an increase of 9.37% compared to the previous year's $950,000. Losses were -$9.93 million, -17.05% less than in 2022.

Financial Statements

News

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-m...

7 days ago - GlobeNewsWire

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its ...

13 days ago - GlobeNewsWire

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx Co...

17 days ago - GlobeNewsWire

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 ...

5 weeks ago - GlobeNewsWire

IntelGenx Launches Preferred Share Regulation A Offering

SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 ...

5 weeks ago - GlobeNewsWire

IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®

SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreemen...

3 months ago - GlobeNewsWire

IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced subsequent...

4 months ago - GlobeNewsWire

IntelGenx Announces Shareholder Approval of Financing Transactions

SAINT LAURENT, Quebec, Nov. 28, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) is pleased to announce that, at its meeting held earlier tod...

4 months ago - GlobeNewsWire

IntelGenx Receives Approval to Conduct 'MONTPARK' Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024 Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024

4 months ago - GlobeNewsWire

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

SAINT LAURENT, Quebec, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) wishes to remind its shareholders of record as of October 2,...

4 months ago - GlobeNewsWire

IntelGenx Reports Third Quarter 2023 Financial Results

SAINT LAURENT, Quebec, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended...

4 months ago - GlobeNewsWire

IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray

IntelGenx to Manufacture and Supply Three New Filmstrip Products: CBD20, THC10, and THC10:CBD10 IntelGenx to Manufacture and Supply Three New Filmstrip Products: CBD20, THC10, and THC10:CBD10

5 months ago - GlobeNewsWire

IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow

SAINT LAURENT, Quebec, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its t...

5 months ago - GlobeNewsWire

IntelGenx Provides RIZAFILM® U.S. Commercialization Update

SAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has received the first purchase order (“PO”) for ...

6 months ago - GlobeNewsWire

IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)

SAINT LAURENT, Quebec, Aug. 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the first tranche of a non-brokered...

7 months ago - GlobeNewsWire

IntelGenx Reports Second Quarter 2023 Financial Results

SAINT LAURENT, Quebec, Aug. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ende...

8 months ago - GlobeNewsWire

IntelGenx Announces First Agreement for CDMO Packaging Services

Expected to generate approximately $9 million in revenue for IntelGenx over three years Expected to generate approximately $9 million in revenue for IntelGenx over three years

8 months ago - GlobeNewsWire

IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow

SAINT LAURENT, Quebec, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its s...

8 months ago - GlobeNewsWire

IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson's Disease

- Manufacturing of both active and placebo films underway for planned 18-month study - - Manufacturing of both active and placebo films underway for planned 18-month study -

8 months ago - GlobeNewsWire

IntelGenx Announces a Change to its Board of Directors

SAINT-LAURENT, Quebec, July 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Mr. J. Bernard (Bernie) Boudr...

8 months ago - GlobeNewsWire

IntelGenx Announces Voting Results on Election of Directors

SAINT LAURENT, Quebec, July 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of t...

9 months ago - GlobeNewsWire

IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow

SAINT LAURENT, Quebec, May 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fi...

11 months ago - GlobeNewsWire

IntelGenx Extends Period to Exercise Certain Warrants

SAINT LAURENT, Quebec, April 27, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) announces that it has received conditional approval from ...

11 months ago - GlobeNewsWire

IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine

Partner Gensco® Pharma preparing to commercially launch RIZAFILM® across the United States as soon as is practicable Partner Gensco® Pharma preparing to commercially launch RIZAFILM® across the United...

1 year ago - GlobeNewsWire

IntelGenx Announces Organizational Changes to Support Global Growth Strategy

SAINT LAURENT, Quebec, April 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced various changes to its management team. Foll...

1 year ago - GlobeNewsWire